Britta Vormoor, MD, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses a Phase I/II trial (NCT03705507) investigating selumetinib, a MEK1/2 inhibitor, combined with dexamethasone in the treatment of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Despite initial safety concerns, successfully addressed through dose adjustments, 44% of participants achieved complete remission, underscoring the potential promise of this combination in the treatment of ALL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.